Thierry Abribat
Vorstandsvorsitzender bei Millendo Therapeutics SAS
Profil
Thierry Abribat is the founder.
He founded Millendo Therapeutics SAS in 2007 and currently holds the title of President & Chief Executive Officer.
He also founded Amolyt Pharma SAS in 2014 and currently holds the title of Chief Executive Officer & Director.
Dr. Abribat's former job positions include being the Chief Executive Officer of EUSA Pharma SAS from 2005 to 2007.
He also served as a Director at Millendo Therapeutics US, Inc. and as the Chief Scientific Officer & EVP-Business Development at Theratechnologies, Inc. Additionally, he worked as a Scientist at Sanofi.
Dr. Abribat obtained a doctorate degree from Institut National Polytechnique de Toulouse.
Aktive Positionen von Thierry Abribat
| Unternehmen | Position | Beginn |
|---|---|---|
Millendo Therapeutics SAS
 Millendo Therapeutics SAS Medical SpecialtiesHealth Technology Millendo Therapeutics SAS provides pharmaceutical research services. It engages in the development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases and rare diseases. The company was founded by Thierry Abribat, André de Villers, Ezio Ghigo and Aart Jan van der Lely on April 23, 2007 and is headquartered in Ecully, France. | Vorstandsvorsitzender | 08.09.2009 |
Amolyt Pharma SAS
 Amolyt Pharma SAS Pharmaceuticals: MajorHealth Technology Amolyt Pharma SAS engages in development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases. The company was founded by Thierry Abribat in 2014 and is headquartered in Ecully, France. | Gründer | 30.07.2014 |
Ehemalige bekannte Positionen von Thierry Abribat
| Unternehmen | Position | Ende |
|---|---|---|
EUSA Pharma SAS
 EUSA Pharma SAS BiotechnologyHealth Technology EUSA Pharma SAS specializes in pharmaceutical research for rare diseases. The company was founded by Gilles Alberici on September 24, 1999 and is headquartered in Limonest, France. | Vorstandsvorsitzender | 01.01.2007 |
Millendo Therapeutics US, Inc.
 Millendo Therapeutics US, Inc. Pharmaceuticals: MajorHealth Technology Millendo Therapeutics US, Inc. engages in the development of novel treatment for adrenal cancer. It focuses on developing a portfolio of disease-modifying treatments for endocrine disorders caused by hormone dysregulation. The company was founded by Raili E. Kerppola, Julia C. Owens, and Gary D. Hammer in January 2012 and is headquartered in Ann Arbor, MI. | Direktor/Vorstandsmitglied | - |
| THERATECHNOLOGIES INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
| SANOFI | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Thierry Abribat
| Institut National Polytechnique de Toulouse | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| SANOFI | Health Technology |
| THERATECHNOLOGIES INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Millendo Therapeutics SAS
Millendo Therapeutics SAS Medical SpecialtiesHealth Technology Millendo Therapeutics SAS provides pharmaceutical research services. It engages in the development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases and rare diseases. The company was founded by Thierry Abribat, André de Villers, Ezio Ghigo and Aart Jan van der Lely on April 23, 2007 and is headquartered in Ecully, France. | Health Technology |
EUSA Pharma SAS
EUSA Pharma SAS BiotechnologyHealth Technology EUSA Pharma SAS specializes in pharmaceutical research for rare diseases. The company was founded by Gilles Alberici on September 24, 1999 and is headquartered in Limonest, France. | Health Technology |
Amolyt Pharma SAS
Amolyt Pharma SAS Pharmaceuticals: MajorHealth Technology Amolyt Pharma SAS engages in development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases. The company was founded by Thierry Abribat in 2014 and is headquartered in Ecully, France. | Health Technology |
Millendo Therapeutics US, Inc.
Millendo Therapeutics US, Inc. Pharmaceuticals: MajorHealth Technology Millendo Therapeutics US, Inc. engages in the development of novel treatment for adrenal cancer. It focuses on developing a portfolio of disease-modifying treatments for endocrine disorders caused by hormone dysregulation. The company was founded by Raili E. Kerppola, Julia C. Owens, and Gary D. Hammer in January 2012 and is headquartered in Ann Arbor, MI. | Health Technology |